/Companies

EdiGene

13 known investors

Find your way into EdiGene

Sign up to find every way you can get introduced to EdiGene

  • Your email: who you already know at EdiGene, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the EdiGene team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform. It focuses on treatments for genetic diseases and cancer.

Investors · 13

Also in the syndicate · 4

Huagai CapitalLilly Asia VentureLoyal Valley CapitalleadSequoia Capital China

Funding

SEC filings, press & company announcements

$62M disclosed across 1 of 3 rounds · 2018–2021

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does EdiGene do?
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform. It focuses on treatments for genetic diseases and cancer.
Who are EdiGene's investors?
EdiGene's investors include LAV, Lilly Asia Ventures, WI Harper Group, 3H Health Investment, Alwin Capital, BioTrack Capital, IDG Capital, Kunlun Capital and 1 more.
How much funding has EdiGene raised?
EdiGene has disclosed $62M raised across 1 of its 3 known rounds.